Boston Scientific Corp BSX
We take great care to ensure that the data presented and summarized in this overview for BOSTON SCIENTIFIC CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BSX
View all-
Vanguard Group Inc Valley Forge, PA135MShares$14 Billion0.25% of portfolio
-
Black Rock Inc. New York, NY126MShares$13.2 Billion0.22% of portfolio
-
State Street Corp Boston, MA64.5MShares$6.73 Billion0.28% of portfolio
-
Primecap Management CO Pasadena, CA36.5MShares$3.81 Billion3.11% of portfolio
-
Wellington Management Group LLP Boston, MA33.2MShares$3.46 Billion0.67% of portfolio
-
Geode Capital Management, LLC Boston, MA31.8MShares$3.32 Billion0.26% of portfolio
-
Bank Of America Corp Charlotte, NC31.6MShares$3.29 Billion0.26% of portfolio
-
Jpmorgan Chase & CO New York, NY31.5MShares$3.29 Billion0.25% of portfolio
-
Capital World Investors Los Angeles, CA28.6MShares$2.98 Billion0.49% of portfolio
-
Bollard Group LLC Boston, MA20.5MShares$2.14 Billion54.28% of portfolio
Latest Institutional Activity in BSX
Top Purchases
Top Sells
About BSX
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Insider Transactions at BSX
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jul 01
2025
|
Vance R Brown SVP, GC and Corp. Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
1,952
-5.51%
|
$203,008
$104.78 P/Share
|
Jul 01
2025
|
Vance R Brown SVP, GC and Corp. Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
4,036
+10.23%
|
-
|
Jul 01
2025
|
Joseph Michael Fitzgerald EVP & Group Pres, Cardiology |
SELL
Open market or private sale
|
Direct |
50,000
-21.9%
|
$5,300,000
$106.97 P/Share
|
Jul 01
2025
|
Joseph Michael Fitzgerald EVP & Group Pres, Cardiology |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+17.96%
|
$1,300,000
$26.15 P/Share
|
Jun 04
2025
|
Joseph Michael Fitzgerald EVP & Group Pres, Cardiology |
SELL
Open market or private sale
|
Direct |
56,372
-24.02%
|
$5,749,944
$102.88 P/Share
|
Jun 04
2025
|
Joseph Michael Fitzgerald EVP & Group Pres, Cardiology |
BUY
Exercise of conversion of derivative security
|
Direct |
56,372
+19.37%
|
$1,465,672
$26.15 P/Share
|
Jun 02
2025
|
Michael F Mahoney Chairman, President & CEO |
SELL
Open market or private sale
|
Direct |
164,443
-5.14%
|
$16,937,629
$103.72 P/Share
|
Jun 02
2025
|
Michael F Mahoney Chairman, President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
105,619
+3.17%
|
$2,112,380
$20.91 P/Share
|
May 29
2025
|
Edward J Ludwig Director |
SELL
Open market or private sale
|
Direct |
4,000
-15.11%
|
$416,000
$104.59 P/Share
|
May 21
2025
|
Vance R Brown SVP, GC and Corp. Secretary |
SELL
Open market or private sale
|
Direct |
4,826
-13.33%
|
$511,556
$106.42 P/Share
|
May 08
2025
|
John E Sununu Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,081
+3.66%
|
-
|
May 08
2025
|
David S Wichmann Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,081
+4.77%
|
-
|
May 08
2025
|
Ellen M Zane Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,081
+5.32%
|
-
|
May 08
2025
|
Yoshiaki Fujimori Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,081
+29.46%
|
-
|
May 08
2025
|
David C Habiger Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,081
+26.99%
|
-
|
May 08
2025
|
Edward J Ludwig Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,081
+7.29%
|
-
|
May 08
2025
|
Jessica L Mega Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,081
+20.17%
|
-
|
May 08
2025
|
Susan E Morano Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,686
+17.0%
|
-
|
May 05
2025
|
John Bradley Sorenson EVP, Global Operations |
SELL
Open market or private sale
|
Direct |
4,572
-19.64%
|
$475,488
$104.54 P/Share
|
May 02
2025
|
Arthur C Butcher EVP& Grp Pres, MedSurg & APAC |
SELL
Payment of exercise price or tax liability
|
Direct |
1,017
-4.18%
|
$105,768
$104.93 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 285K shares |
---|---|
Exercise of conversion of derivative security | 1.31M shares |
Bona fide gift | 210K shares |
Discretionary transaction | 10.8K shares |
Open market or private purchase | 50 shares |
Bona fide gift | 207K shares |
---|---|
Open market or private sale | 1.61M shares |
Payment of exercise price or tax liability | 244K shares |